MediWound Ltd. announced the appointment of Roland Frösing as the company's European Medical Director in support of its planned advancement of the EscharEx program for the debridement of chronic wounds as well as its efforts to expand market access and reimbursement for NexoBrid. Before joining the company, Roland served as Global Medical Director and head of Market Access at Mölnlycke Health Care, where he led the global medical development and market access activities worldwide.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.95 USD | -3.75% | -1.97% | +66.67% |
03-21 | MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026 | CI |
03-21 | Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.67% | 163M | |
-1.62% | 89.22B | |
+1.32% | 40.49B | |
-15.51% | 32.79B | |
+64.13% | 26.23B | |
-21.95% | 14.52B | |
-7.77% | 13.09B | |
-44.07% | 11.6B | |
-13.06% | 11.5B | |
+4.94% | 8.82B |
- Stock Market
- Equities
- MDWD Stock
- News MediWound Ltd.
- MediWound Ltd. Appoints Roland Frosing as European Medical Director